U.S. Markets open in 13 mins

Allergan Declares Second Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share

- Dividend to be Paid on June 14, 2019 -

- Record Date of May 14, 2019 -

DUBLIN, May 3, 2019 /PRNewswire/ -- Allergan plc (AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the second quarter of 2019. The dividend will be paid on June 14, 2019 to shareholders of record at the close of business on May 14, 2019.

Allergan plc logo

About Allergan plc

Allergan plc (AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:      

Allergan:
Investors:
Manisha Narasimhan, PhD
(862) 261-7162

Christine Chiou
(862) 261-7396

Media: 
Amy Rose
(862) 289-3072

Lisa Brown
(862) 261-7320

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/allergan-declares-second-quarter-2019-cash-dividend-of-0-74-per-ordinary-share-300843115.html